Overview

Phase I Study to Evaluate SCR-6852 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Status:
Not yet recruiting

Trial end date:
2025-09-08

Target enrollment:

Participant gender:

Summary

This study is a multi-center, open-label, Phase 1 clinical study to evaluate the safety, kinetics and anti-tumor efficacy of SCR-6852 and SCR-6852 in combination with palbociclib in subjects with estrogen receptor (ER) -positive, human epidermal growth factor receptor (HER-2) -negative locally advanced or metastatic breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Treatments:

Palbociclib